Huang, Xizhong,Peters, Malte,Cao, Zhu Alexander,Gansert, Jennifer Lorraine,Chang, David Dong Eun,Beltran, Pedro
申请号：
AU2013235596
公开号：
AU2013235596B2
申请日:
2013.03.13
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
The present invention relates to a pharmaceutical combination comprising a MEK inhibitor compound 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)- amide or a pharmaceutically acceptable salt thereof and the IGF1R inhibitor ANTIBODY A, a pharmaceutical composition comprising such combination, methods for treating cancer comprising administration of a therapeutically effective amount of such combination to a subject in need thereof, and uses of such combination for the treatment of cancer.
